CommercialCoverageMedium impact
08.00.74x, Intravitreal Injection of Vascular Endothelial Growth Factor (VEGF) Antagonists, VEGF Biosimilars, and Combination VEGF/Angiopoietin-2 (Ang-2) Inhibitors
Independence Blue Cross·Ophthalmology·Pharmacy
Effective date
Jan 1, 2025
We identified it
Jun 19, 2026
Summary
The medical necessity criteria for intravitreal injection of VEGF antagonists, VEGF biosimilars, and combination VEGF/Angiopoietin-2 inhibitors have been updated. This affects coverage requirements for eye injections used to treat conditions like macular degeneration and diabetic retinopathy.
Action Required
Before January 1, 2025: Billing team and ophthalmology providers must review updated medical necessity criteria for intravitreal VEGF injections at https://medpolicy.ibx.com/ibc/Commercial/Pages/Site-Activity-View.aspx?FilterField1=MPSiteActivityLogMonth&FilterValue1=01&FilterField2=MPSiteActivityLogYear&FilterValue2=2025#commercial-08-00-74x. Update prior authorization processes and documentation requirements accordingly. Ensure providers document medical necessity per new criteria to avoid claim denials.